Follow this link to study information, which will expand over time.
The Cancer Letter: NCI-MATCH Keeps Enrolling (a series of three in-depth articles, including a Q&A with ECOG-ACRIN study chair, Keith T. Flaherty, MD)
Business Wire: Alliance Foundation Trials Opens Global Trial Investigating First-in-Class Palbociclib in HR+, HER2+ Metastatic Breast Cancer (PrECOG, LLC is part of this trial)
Clinical Oncology News: Consider Neoadjuvant Targeted Therapy for RCC (mentions the EA8143 aka PROSPER RCC trial; free registration required for access)
Welcome to the ECOG-ACRIN Cancer Research Group website, the source of information about the cooperative group that was formed by the merger of the Eastern Cooperative Oncology Group (ECOG) and the American College of Radiology Imaging Network (ACRIN). We are excited to share news of our collaborative effort to design and conduct ground-breaking translational and clinical research.
The merger brought together the strengths and capabilities of two highly respected organizations. Since 1955, ECOG has performed practice-changing multicenter cancer clinical trials, working with more than 6000 physicians, nurses, pharmacists, statisticians, clinical research associates, and cancer research advocates from the United States and around the world. ACRIN, the premier imaging science program in the nation, complements ECOG’s research efforts with its expertise in early detection, imaging diagnosis, comparative-effectiveness research, and cost-effectiveness analysis. Now, as a single entity, we aim to achieve earlier cancer detection, more successful therapeutic intervention, higher rates of prevention, and better patient outcomes.
We look forward to sharing our research and partnering with you, as we reshape the future of patient care.
Robert L. Comis, MD